Cord Blood Transplantation for Patients With Cancer

Hematological Disease Clinical Trial

Official title: Combined Transplantation of Unmanipulated Haploidentical and a SingleCord Blood Unit for Patients With Hematologic Malignancies

Status Terminated

Clinical Trial Summary

The primary objective of this study is to assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific antibodies and in those with active disease.

Clinical Trial Description

Primary Objective

• To assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific anti-HLA antibodies and in those with active disease

Secondary Objectives

• To determine the long term fate of the haplo transplant and the cord blood transplant in this setting.

• To describe the incidence and severity of acute and chronic GVHD. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hematologic Diseases
• Hematological Disease

• NCT number: NCT01359254
• Study type: Interventional
• Source: University of Chicago
• Status: Terminated
• Phase: Phase 2
• Start date: April 2010
• Completion date: June 2012